Home›Trial›NCT06712823

🔬NCT06712823Phase 2RECRUITING

An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894

Study Summary

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of atumelnant (CRN04894).

Conditions

Congenital Adrenal Hyperplasia Classic Congenital Adrenal Hyperplasia

Interventions / Drugs

atumelnant (CRN04894)

View on ClinicalTrials.gov ↗

Sponsor

Crinetics Pharmaceuticals

Study Details

Enrollment150 participants

Primary Completion—

Lead SponsorCrinetics Pharmaceuticals Inc.

Data Retrieved2026-04-11 04:10:51.260415+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.